Singapore markets closed

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
3.8100-0.0200 (-0.52%)
At close: 03:59PM EDT
Currency in CAD

Valuation measures4

Market cap (intra-day) 135.72M
Enterprise value 99.81M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)5.09
Enterprise value/revenue N/A
Enterprise value/EBITDA -3.88

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-45.57%
S&P500 52-week change 324.78%
52-week high 39.1000
52-week low 33.4400
50-day moving average 33.9424
200-day moving average 35.7181

Share statistics

Avg vol (3-month) 364.27k
Avg vol (10-day) 324.83k
Shares outstanding 535.62M
Implied shares outstanding 635.62M
Float 824.19M
% held by insiders 16.93%
% held by institutions 111.89%
Shares short (15 May 2024) 415.33k
Short ratio (15 May 2024) 40.43
Short % of float (15 May 2024) 40.07%
Short % of shares outstanding (15 May 2024) 40.04%
Shares short (prior month 15 Apr 2024) 4800

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)-246.24%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -30.89M
Net income avi to common (ttm)-30.37M
Diluted EPS (ttm)-1.6400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)35.91M
Total cash per share (mrq)1.25
Total debt (mrq)9.56M
Total debt/equity (mrq)52.78%
Current ratio (mrq)1.95
Book value per share (mrq)0.68

Cash flow statement

Operating cash flow (ttm)-22.24M
Levered free cash flow (ttm)N/A